Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL [Phase 2]

View source ↗

Summary

Phase II clinical trial investigating the efficacy and safety of F520 in combination with F007 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• F007
• F520

Snippet

Sponsor: Shandong New Time Pharmaceutical Co., LTD | Conditions: RR DLBCL; PD-1; CD20 | Phase 2 | Status: UNKNOWN